0
SELLAS Life Sciences Group, Inc. Banner Image

SELLAS Life Sciences Group, Inc.

  • Ticker SLS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
SELLAS Life Sciences Group, Inc. Logo Image
  • 1-10 Employees
  • Based in Zurich, Switzerland
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to addressMore a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S, is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.
REPORT RATINGS
4.8 / 5.0 (207)

SELLAS Life Sciences Group, Inc. reports have an aggregate usefulness score of 4.8 based on 207 reviews.

SELLAS Life Sciences Group, Inc.

Most Recent Annual Report

SELLAS Life Sciences Group, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

SELLAS Life Sciences Group, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!